[go: up one dir, main page]

PE20081510A1 - Derivados de dihidropiridina como inhibidores de la proteina quinasa - Google Patents

Derivados de dihidropiridina como inhibidores de la proteina quinasa

Info

Publication number
PE20081510A1
PE20081510A1 PE2007001781A PE2007001781A PE20081510A1 PE 20081510 A1 PE20081510 A1 PE 20081510A1 PE 2007001781 A PE2007001781 A PE 2007001781A PE 2007001781 A PE2007001781 A PE 2007001781A PE 20081510 A1 PE20081510 A1 PE 20081510A1
Authority
PE
Peru
Prior art keywords
amino
alkyl
indazol
dihydro
dimethyl
Prior art date
Application number
PE2007001781A
Other languages
English (en)
Inventor
Guido Adler
Stefan Baeurle
Judi Bryant
Ming Chen
Yuo-Ling Chou
Paul Hrvatin
Seock-Kyu Khim
Monica J Kochanny
Wheeseong Lee
Michael Mamounas
Janet Meurer
Gary Bruce Phillips
Victor Selchau
Christopher West
Bin Ye
Shendong Yuang
Martin Krueger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39262588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20081510A1 publication Critical patent/PE20081510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN DERIVADO DE DIHIDROPIRIDINA DE FORMULA (I), DONDE R1 ES H, ALQUILO C1-C12, HALOALQUILO C1-C12, HIDROXIALQUILO C1-C12, ENTRE OTROS; R2 SE SELECCIONA DE R2-1, R2-2, R2-3 O R2-4; A Y B SON CR11 O N; D Y E SON NR12 O S; W, Y, X Y Z SON CR11, CR14 O N; n ES 1, 2 O 3; R3 ES H, CIANO, ALQUILO C1-C12, ENTRE OTROS; R4 ES HALOALQUILO C1-C2, ARILO, HETEROARILO, ENTRE OTROS; R5 ES H, ARALQUILO, R7, ENTRE OTROS; R6 ES ALQUILO C1-C3 O AMINO; R7 ES ALQUILO C1-C12, CICLOALQUILO, ARILO, ENTRE OTROS; R11 ES H, HALO, AMINO, NHC(=O)R7, ENTRE OTROS; R12 ES H, AMINO, ALQUILO C1-C12, ENTRE OTROS; R14 ES H, HALO, AMINO, NHR7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1,4-DIHIDRO-4-(1H-INDAZOL-5-IL)-2,6-DIMETIL-3,5-PIRIDINDICARBONITRILO, 4-(3-AMINO-1H-INDAZOL-5-IL)-1,4-DIHIDRO-2,6-DIMETIL-3,5-PIRIDINDICARBONITRILO, 1,4-DIHIDRO-4-[3-(3-METOXIFENIL)-1H-INDAZOL-5-IL]-2,6-DIMETIL-3,5-PIRIDINCARBONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEINA TIROSINA QUINASAS, PARTICULARMENTE, C-TET QUINASA Y SON UTILES EN EL TRATAMIENTO DE CANCERES
PE2007001781A 2006-12-14 2007-12-13 Derivados de dihidropiridina como inhibidores de la proteina quinasa PE20081510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87512406P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
PE20081510A1 true PE20081510A1 (es) 2008-12-12

Family

ID=39262588

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001781A PE20081510A1 (es) 2006-12-14 2007-12-13 Derivados de dihidropiridina como inhibidores de la proteina quinasa

Country Status (31)

Country Link
US (1) US8198456B2 (es)
EP (1) EP2121608B1 (es)
JP (2) JP2010513231A (es)
KR (1) KR20090087919A (es)
CN (1) CN101558040B (es)
AR (1) AR064349A1 (es)
AU (1) AU2007331676A1 (es)
BR (1) BRPI0719991A2 (es)
CA (1) CA2672167C (es)
CL (1) CL2007003609A1 (es)
CO (1) CO6210730A2 (es)
CR (1) CR10868A (es)
CU (1) CU23828A3 (es)
DO (1) DOP2009000141A (es)
EA (1) EA200900779A1 (es)
EC (1) ECSP099414A (es)
ES (1) ES2396160T3 (es)
HN (1) HN2009001165A (es)
IL (1) IL198171A0 (es)
MA (1) MA31090B1 (es)
MX (1) MX2009006267A (es)
MY (1) MY148851A (es)
NO (1) NO20092651L (es)
NZ (1) NZ577611A (es)
PE (1) PE20081510A1 (es)
SG (1) SG177200A1 (es)
SV (1) SV2009003299A (es)
TN (1) TN2009000128A1 (es)
TW (1) TW200836729A (es)
UY (1) UY30779A1 (es)
WO (1) WO2008071451A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156757A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2009149837A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof
JP5480891B2 (ja) * 2008-06-09 2014-04-23 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アネレート化４−（インダゾリル）−１，４−ジヒドロピリジン誘導体およびそれらの使用方法
CN102348702B (zh) * 2009-02-18 2014-01-29 拜耳知识产权有限责任公司 二环和三环吲唑-取代的1,4-二氢吡啶衍生物及其用途
CN102639537B (zh) * 2009-07-10 2015-07-22 拜耳知识产权有限责任公司 吲唑基取代的二氢异*唑并吡啶及其使用方法
HRP20151425T1 (hr) 2009-08-10 2016-01-29 Samumed, Llc Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
UY32922A (es) * 2009-10-06 2011-04-29 Bayer Schering Pharma Ag Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
ES2466815T3 (es) 2009-10-06 2014-06-11 Bayer Intellectual Property Gmbh 2,6-dialquil-3,5-diciano-4-(1H-indazol-5-il)-1,4-dihidropiridinas fluoradas y procedimientos de uso de las mismas
CA2777907C (en) 2009-11-11 2017-08-29 Bayer Pharma Aktiengesellschaft Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
WO2011061157A1 (en) 2009-11-18 2011-05-26 Bayer Schering Pharma Aktiengesellschaft Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CA2784753A1 (en) 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Substituted aminothiazolone indazoles as estrogen related receptor-.alpha. modulators
HUE035612T2 (en) 2009-12-21 2018-05-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
WO2012129338A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
RU2627693C2 (ru) 2011-09-14 2017-08-10 СЭМЬЮМЕД, ЭлЭлСи ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/b-КАТЕНИНА
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
CN103319456B (zh) * 2012-03-23 2015-05-13 上海汇伦生命科技有限公司 二氢吡啶类化合物、其组合物、制备方法和用途
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
SG10201710585UA (en) 2012-05-04 2018-02-27 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
MX370487B (es) 2013-01-08 2019-12-16 Samumed Llc Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
BR112016015449A8 (pt) * 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
CN107072985B (zh) * 2014-07-16 2020-02-07 莱福斯希医药公司 治疗性抑制化合物
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
MX389958B (es) 2015-11-06 2025-03-20 Samumed Llc 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
SG11201809173TA (en) 2016-04-20 2018-11-29 Bristol Myers Squibb Co Substituted bicyclic heterocyclic compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
RS63813B1 (sr) 2016-06-01 2023-01-31 Biosplice Therapeutics Inc Postupak pripreme n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
EP3480201A1 (en) * 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
US20210047297A1 (en) 2018-03-28 2021-02-18 Bayer Pharma Aktiengesellschaft 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
CN110078707A (zh) * 2019-06-03 2019-08-02 上海贤鼎生物科技有限公司 一种2-(1H-苯并[d]咪唑-2-基)-8-羟基喹啉的合成方法
CN116969891A (zh) * 2023-07-28 2023-10-31 杭州国瑞生物科技有限公司 一种7-甲基-5-醛基-1h-吲唑的合成方法
WO2025170939A1 (en) * 2024-02-05 2025-08-14 The Board Of Regents Of The University Of Texas System Proteasome inhibitors for the treatment of malaria

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS162291B1 (es) * 1973-04-26 1975-07-15
PL86477B1 (es) * 1973-09-01 1976-05-31
CS168272B1 (es) 1973-09-18 1976-05-28
GB1457787A (en) * 1974-05-17 1976-12-08 Wyeth John & Brother Ltd Dihydropyridines
CS191511B1 (en) * 1976-09-06 1979-07-31 Jaroslav Palecek Process for preparing 1-dialkylaminoalkyl-2,6-dimethyl-4-/y-substituted phenyl/-3,5-disubstituted 1,4-dihydropyridines
GB9515445D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa Dihydropyridine and pyridine derivatives and process for their preparation
US6265127B1 (en) 1999-12-15 2001-07-24 Eastman Kodak Company 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
MXPA06000276A (es) 2003-07-02 2006-04-07 Sugen Inc Indolinona hidrazidas como inhibidores de c-met.
JP2007230869A (ja) * 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
EP1784396B8 (en) 2004-08-26 2011-04-20 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ES2390227T3 (es) 2004-09-09 2012-11-07 Natco Pharma Limited Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
RU2007126551A (ru) 2004-12-13 2009-01-20 Айрм Ллк (Bm) Соединения и композиции, как модуляторы стероидных рецепторов и активности кальциевых каналов
EP1858325A4 (en) 2005-01-07 2010-06-30 Roskamp Res Llc COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION AND METHODS FOR IDENTIFYING THESE COMPOUNDS
KR20080110912A (ko) * 2006-04-19 2008-12-19 노파르티스 아게 인다졸 화합물 및 ｃｄｃ７의 억제 방법

Also Published As

Publication number Publication date
MX2009006267A (es) 2009-06-22
DOP2009000141A (es) 2009-07-15
NO20092651L (no) 2009-09-14
KR20090087919A (ko) 2009-08-18
US20080176833A1 (en) 2008-07-24
IL198171A0 (en) 2009-12-24
AU2007331676A1 (en) 2008-06-19
ES2396160T8 (es) 2013-03-22
CR10868A (es) 2009-07-23
CU23828B1 (es) 2012-06-29
EA200900779A1 (ru) 2010-02-26
EP2121608A1 (en) 2009-11-25
WO2008071451A1 (en) 2008-06-19
ECSP099414A (es) 2009-07-31
CU20090107A7 (es) 2012-02-15
ES2396160T3 (es) 2013-02-19
UY30779A1 (es) 2008-07-31
AR064349A1 (es) 2009-04-01
CU23828A3 (es) 2012-06-29
HN2009001165A (es) 2011-11-03
CA2672167C (en) 2016-01-26
JP2014139197A (ja) 2014-07-31
US8198456B2 (en) 2012-06-12
CN101558040B (zh) 2013-03-27
JP6021838B2 (ja) 2016-11-09
EP2121608B1 (en) 2012-11-14
BRPI0719991A2 (pt) 2014-03-18
TN2009000128A1 (en) 2010-10-18
HK1135103A1 (en) 2010-05-28
SV2009003299A (es) 2009-12-14
CA2672167A1 (en) 2008-06-19
CO6210730A2 (es) 2010-10-20
JP2010513231A (ja) 2010-04-30
NZ577611A (en) 2012-01-12
SG177200A1 (en) 2012-01-30
MY148851A (en) 2013-06-14
CL2007003609A1 (es) 2008-07-25
CN101558040A (zh) 2009-10-14
TW200836729A (en) 2008-09-16
MA31090B1 (fr) 2010-01-04

Similar Documents

Publication Publication Date Title
PE20081510A1 (es) Derivados de dihidropiridina como inhibidores de la proteina quinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20060197A1 (es) Heterociclos biciclicos como inhibidores de cinasa
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20080005A1 (es) Derivados de cromanol sustituidos como agentes inhibidores de cetp
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20141681A1 (es) Inhibidores de btk
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
DE602005024239D1 (de) Pyrimidin-verbindungen als purin-rezeptorantagonisten
PE20091849A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed